Merck's Keytruda has breast cancer activity; combo trials next
This article was originally published in Scrip
Executive Summary
Merck & Co's Keytruda (pembrolizumab) generated an 18.5% overall response rate (ORR) and caused stable disease in 25.9% of hard-to-treat patients with triple-negative breast cancer (TNBC), justifying future studies of the programmed cell death-1 (PD-1) inhibitor in combination with other breast cancer treatments.